%0 Journal Article
%T Brigatinib: Novel ALK Inhibitor for Non¨CSmall
%A Adia Matthew
%A Angela C. Riley
%A Anthony J. Di Pasqua
%A Sara A. Spencer
%J Annals of Pharmacotherapy
%@ 1542-6270
%D 2019
%R 10.1177/1060028018824578
%X Objective: We review here the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, potential drug-drug interactions and place in therapy of brigatinib for abnormal anaplastic lymphoma kinase (ALK) specific non¨Csmall-cell lung cancer (NSCLC). Data Sources: A literature search using PubMed was conducted using the terms brigatinib and ALK positive NSCLC from January 2013 to November 2018. Study Selection and Data Extraction: All English-language articles evaluating brigatinib were analyzed for this review. Data Synthesis: Brigatinib was granted approval for the treatment of patients with metastatic ALK+ NSCLC who have progressed on or are intolerant to crizotinib. It is administered at a dose of 90 mg orally once daily for the first 7 days then, if tolerated, increased to a dose of 180 mg orally once daily. Common adverse effects include nausea, fatigue, diarrhea, increased creatine phosphokinase levels, headache, dyspnea, and hypertension. Serious treatment-emergent adverse effects were pulmonary related. Relevance to Patient Care and Clinical Practice: This article discusses the clinical trials that led to the accelerated approval of brigatinib for its ability to overcome crizotinib-resistant mutations and for its increased central nervous system penetration properties. Conclusion: Brigatinib was granted accelerated approval for the treatment of patients with metastatic ALK+ NSCLC who have progressed on or are intolerant to crizotinib. In a subset of NSCLC patients, brigatinib increases survival for approximately 1 year; however, side effects were detected
%K brigatinib
%K anaplastic lymphoma kinase (ALK)
%K non¨Csmall-cell lung cancer (NSCLC)
%K tyrosine kinase inhibitor
%U https://journals.sagepub.com/doi/full/10.1177/1060028018824578